Sign up
Pharma Capital

Neutralstem shares pop on FDA orphan drug decision

The drug is being developed to treat a genetic disorder called Angelman syndrome, which can cause seizures
biopharmaceutical company
Neuralstem is a biopharmaceutical firm developing nervous system therapies based on its stem cell technology

Neuralstem Inc (NASDAQ:CUR) shares got a jolt to higher territory on Thursday after the US Food and Drug Administration granted orphan drug approval for its drug treatment of a rare disease called Angelman syndrome.

The drug is called NSI-189 and orphan drug designation gives companies special status and incentives to encourage the development of drugs for diseases affecting fewer than 200,000 people in the US.

Neuralstem shares gained 6.3% to trade at US$1.18, having hit a peak of US$1.35.

READ: Neuralstem jumps after surgery to repair spinal cord injuries shows positive results

According to the Mayo clinic, Angelman syndrome is a genetic disorder that causes developmental disabilities, neurological problems and, sometimes, seizures. It is caused by a genetic mutation called UBE3A. Normally, people inherit one copy of the gene from each parent. In Angelman, part of the maternal copy is missing or damaged.

People with Angelman syndrome often smile and laugh frequently, and have happy, excitable personalities, the clinic said. Developmental delays, between about six and 12 months of age, are usually the first signs of Angelman syndrome. Seizures often begin between the ages of two and three years old.

People with Angelman syndrome tend to live a normal life span, but the disease cannot be cured. Treatment focuses on managing medical and developmental issues.

Neuralstem is based in Germantown, Maryland. It is a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology.



Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.